Both Rice University and the University of Houston were recognized recently on national rankings. Photo via Getty Images

Two new rankings have put the University of Houston and Rice University in the academic limelight.

UH ranks 60th on the National Academy of Inventors’ list of the top 100 universities for utility patents granted last year in the U.S. Meanwhile, Rice has moved up dramatically on Bloomberg Businessweek’s annual list of the top full-time MBA programs.

In 2022, UH received 32 utility patents. The university explains that utility patents are among the world’s most valuable assets because they give inventors exclusive commercial rights for producing and using their technology.

UH joins the University of Texas (No. 3), Texas A&M University (No. 37), Texas Tech University (tie for No. 75), and Baylor University (tie for No. 75) as the only Texas schools on the patent list.

“This recognition further underscores our commitment to innovation and the impactful research taking place at UH,” says Ramanan Krishnamoorti, the university’s vice president of energy and innovation. “It is a testament to the dedication and ingenuity of our faculty, researchers, and students who continue to push the boundaries of knowledge and drive positive change in our world through their hard work and inventive contributions.”

Rice also is sharing in recent academic accolades.

Rice’s Jones Graduate School of Business climbed 10 spots — to No. 19 — in Bloomberg Businessweek’s 2023-24 ranking of full-time MBA programs. Rice holds the No. 1 spot among Texas programs.

The Jones School gained ground in the ranking’s learning, networking, diversity, and entrepreneurship categories.

“Rising in the rankings for networking and diversity shows how Rice’s faculty and staff are dedicated to creating an entire environment and ecosystem that benefits our students, not just what happens inside the classroom,” says Peter Rodriguez, the business dean at Rice. “I am especially proud of these metrics that highlight Rice’s ability to bring people together.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.